Get the Stockscreener App
9.80
0.72%
0.07
After Hours:
9.80
Amicus Therapeutics Inc stock is traded at $9.80, with a volume of 3.36M.
It is up +0.72% in the last 24 hours and up +2.19% over the past month.
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
See More
Previous Close:
$9.73
Open:
$9.68
24h Volume:
3.36M
Relative Volume:
1.31
Market Cap:
$2.93B
Revenue:
$493.67M
Net Income/Loss:
$-104.69M
P/E Ratio:
-15.31
EPS:
-0.64
Net Cash Flow:
$-31.51M
1W Performance:
+4.70%
1M Performance:
+2.19%
6M Performance:
+0.00%
1Y Performance:
-23.68%
1-Day Range:
$9.60
$9.88
1-Week Range:
$9.275
$9.99
52-Week Range:
$9.02
$14.57
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Name
Amicus Therapeutics Inc
Sector
Industry
Phone
(609) 662-2000
Address
47 HULFISH STREET, PRINCETON, NJ
Compare FOLD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
9.80 | 2.93B | 493.67M | -104.69M | -31.51M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-06-24 | Initiated | Jefferies | Buy |
| May-30-24 | Initiated | Wells Fargo | Overweight |
| May-14-24 | Upgrade | Guggenheim | Neutral → Buy |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| Apr-13-22 | Resumed | Goldman | Neutral |
| Jan-14-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-15-21 | Upgrade | Stifel | Hold → Buy |
| Sep-30-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-19-21 | Resumed | BTIG Research | Buy |
| May-27-21 | Initiated | Needham | Hold |
| May-21-21 | Initiated | UBS | Buy |
| Apr-14-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-02-21 | Initiated | Stifel | Hold |
| Feb-12-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-28-20 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-10-20 | Downgrade | Citigroup | Buy → Neutral |
| Nov-11-20 | Initiated | Berenberg | Hold |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Feb-04-20 | Resumed | Cantor Fitzgerald | Overweight |
| Nov-12-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-19 | Initiated | H.C. Wainwright | Buy |
| Jun-05-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-05-19 | Initiated | Janney | Buy |
| Jan-30-19 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-29-18 | Initiated | Citigroup | Neutral |
| Aug-17-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
| Sep-13-17 | Reiterated | Chardan Capital Markets | Buy |
| Aug-10-17 | Reiterated | Chardan Capital Markets | Buy |
| Jan-24-17 | Upgrade | Robert W. Baird | Neutral → Outperform |
| May-18-16 | Initiated | BofA/Merrill | Buy |
| Apr-14-16 | Initiated | Robert W. Baird | Neutral |
| Apr-12-16 | Reiterated | Chardan Capital Markets | Buy |
| Sep-16-15 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jun-16-15 | Reiterated | Chardan Capital Markets | Buy |
View All
Amicus Therapeutics Inc Stock (FOLD) Latest News
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Fabry Disease Treatment Market Growth in Future Scope 2024-2031 - openPR
FOLD: 3 High-Growth Biotech Stocks to Watch - StockNews.com
Amicus Therapeutics (NASDAQ:FOLD) Rating Lowered to "Hold" at StockNews.com - MarketBeat
Y Intercept Hong Kong Ltd Has $374,000 Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Shares Up 5.2%Time to Buy? - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock Position Lessened by Orion Portfolio Solutions LLC - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Shares Gap Down – Here’s What Happened - Defense World
Amicus Therapeutics (NASDAQ:FOLD) Shares Gap DownTime to Sell? - MarketBeat
Morgan Stanley upgrades PTC, cuts Immuneering, Amicus (PTCT:NASDAQ) - Seeking Alpha
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday? - Yahoo Finance
Amicus Therapeutics (FOLD) is a Top-Ranked Momentum Stock: Should You Buy? - MSN
Morgan Stanley cuts Amicus Therapeutics shares to Equalweight rating By Investing.com - Investing.com UK
Amicus Therapeutics' (FOLD) Equal Weight Rating Reaffirmed at Morgan Stanley - MarketBeat
Neo Ivy Capital Management Takes Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 47,310 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Fmr LLC Decreases Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Old West Investment Management LLC Increases Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Upgraded to Buy at StockNews.com - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stake Raised by Wellington Management Group LLP - MarketBeat
Point72 Asset Management L.P. Makes New $13.53 Million Investment in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Why Is Amicus Therapeutics (FOLD) Down 11.1% Since Last Earnings Report? - Yahoo Finance
Point72 DIFC Ltd Invests $704,000 in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Janus Henderson Group PLC Trims Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by Charles Schwab Investment Management Inc. - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock Holdings Cut by Redmile Group LLC - MarketBeat
Parkman Healthcare Partners LLC Has $6.47 Million Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Erste Asset Management GmbH Makes New $1.25 Million Investment in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
BNP Paribas Financial Markets Purchases 225,222 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics CEO Campbell Bradley sells $75,124 in stock - Investing.com India
Amicus Therapeutics CEO Campbell Bradley sells $75,124 in stock By Investing.com - Investing.com UK
Pompe Disease Market is expected to rise at a Significant CAGR, DelveInsight | Pompe Disease Therapies, Clinical trials, Treatment Options, Companies | Genzyme, Sanofi, Amicus Therapeutics, Actus - The Globe and Mail
Pompe Disease Market is expected to rise at a Significant CAGR, - openPR
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock Position Boosted by Edgestream Partners L.P. - MarketBeat
PDT Partners LLC Buys New Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Intech Investment Management LLC Takes $834,000 Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Algert Global LLC Purchases 170,575 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Massachusetts Financial Services Co. MA Has $33.75 Million Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Increases Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Principal Financial Group Inc. Lowers Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
(FOLD) Technical Data - Stock Traders Daily
Here's What Key Metrics Tell Us About Amicus Therapeutics (FOLD) Q3 Earnings - MSN
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Victory Capital Management Inc. - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Rating Increased to Buy at StockNews.com - MarketBeat
Redmile Group, LLC Increases Stake in Amicus Therapeutics Inc - GuruFocus.com
Protein Therapeutics Market Size to be Worth USD 549.4 billion by 2031, at a CAGR of 6.3% | Transparency Market Research, Inc. - GlobeNewswire Inc.
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC Acquires Shares in Amic - GuruFocus.com
Amicus' Q3 Earnings & Revenues Beat Estimates, '24 View Updated - MSN
Avoro Capital Advisors LLC Adjusts Stake in Amicus Therapeutics Inc - GuruFocus.com
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Purchased by GSA Capital Partners LLP - MarketBeat
Amicus Therapeutics Inc Stock (FOLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):